Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management

Size: px
Start display at page:

Download "Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management"

Transcription

1 Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management Table of Contents Policy: Commercial Information Pertaining to All Policies Endnotes Policy: Medicare References Forms Policy History Policy Number: 011 BCBSA Reference Number: None Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Note: All requests for outpatient retail pharmacy for indications listed and not listed on the medical policy guidelines may be submitted to BCBSMA Clinical Pharmacy Operations by completing the Prior Authorization Form on the last page of this document. Physicians may also call BCBSMA Pharmacy Operations department at (800) to request a prior authorization/formulary exception verbally. Physicians may also submit requests for retail pharmacy exceptions via the web using Express PA which can be found on the BCBSMA provider portal or directly on the web at Patients must have pharmacy benefits under their subscriber certificates. Please refer to the chart below for the formulary status of the medications affected by this policy. Standard Formulary Drug Formulary Status STEP 1 Albuterol Aminophylline Budesonide Combivent Cromolyn sodium Covered Epinephrin Zafirlukast Flunisolide Ipratropium-Albuterol 1

2 Levalbuterol Metaproterenol Montelukast Spiriva Terbutaline Theochron Theophylline STEP 2 Dulera * Prior Use of Step 1 Required Singulair * Symbicort * STEP 3 Accolate ** Prior use of Step 1 and Step Advair Diskus * 2 Required Advair HFA* Anoro TM Ellipta TM* Breo TM Ellipta TM** Zyflo ** Zyflo CR ** **Non formulary medications are covered when a formulary exception request is submitted to BCBSMA Pharmacy Operations and step criteria below are met. We cover the medications listed in the chart above for new starts* in the following stepped approach¹: *New start is defined as no previous paid claim for the requested medication within the past 130 days. Dulera (mometasone/formoterol) and Singulair are covered when the following criteria are met: The patient has a physician documented diagnosis of asthma There must be evidence of a paid claim or physician documented use with any ONE of the following: o One inhaled mast cell stabilizer o One oral albuterol product or one oral theophylline containing product by the patient within the previous 130 days There must be evidence of a BCBSMA paid claim of the requested medication by the patient within the previous 130 days. **Requests based exclusively on the use of samples will not meet coverage criteria for exception. Additional clinical information demonstrating medical necessity of the desired medication must be submitted by the requesting prescriber for review. Symbicort (Budesonide/Formoterol) 2 is covered when the following criteria are met: The patient has a physician documented diagnosis of asthma or COPD. There must be evidence of a paid claim or physician documented use with any ONE of the following: 2

3 o One inhaled mast cell stabilizer, one oral albuterol product or one oral theophylline containing product by the patient within the previous 130 days There must be evidence of a BCBSMA paid claim of the requested medication by the patient within the previous 130 days. **Requests based exclusively on the use of samples will not meet coverage criteria for exception. Additional clinical information demonstrating medical necessity of the desired medication must be submitted by the requesting prescriber for review. Accolate, Zyflo (zileuton) or Zyflo CR (zileuton) is covered when a formulary exception request is submitted to BCBSMA Pharmacy Operations and when the following criteria are met: The patient has a physician documented diagnosis of asthma. There must be evidence of a paid claim or physician documented use with any ONE of the following: o One inhaled beta-2 agonist,one inhaled mast cell stabilizer o One oral albuterol product o One oral theophylline containing product by the patient within the previous 130 days. There must be evidence of a BCBSMA paid claim or physician documented use of montelukast, Singulair (montelukast) or zafirlukast by the patient within the previous 130 days. There must be evidence of a BCBSMA paid claim of Accolate, Zyflo (zileuton) or Zyflo CR (zileuton) by the patient within the previous 130 days. Advair Diskus (Fluticasone/Salmeterol) 2 or Advair HFA(Fluticasone/Salmeterol) 2 are covered when the following criteria are met: The patient has a physician documented diagnosis of asthma or COPD There must be evidence of a paid claim or physician documented use with any ONE of the following: o One inhaled mast cell stabilizer o One oral albuterol product o One oral theophylline containing product by the patient within the previous 130 days. There must be evidence of a BCBSMA paid claim or physician documented use of Dulera (mometasone/formoterol) or Symbicort (Budesonide/Formoterol) by the patient within the previous 130 days*, There must be evidence of a BCBSMA paid claim of Advair or Advair HFA by the patient within the previous 130 days *Due to FDA approved labeling, children ages 4-11 years will not be required to meet the previous use Symbicort or Dulera criteria prior to use of Advair. Breo TM Ellipta TM (fluticasone furoate and vilanterol trifenatate) or Anoro TM Ellipta TM (umeclidinium and vilanterol powder) may be covered when the following criteria are met: The patient has a physician documented diagnosis COPD There must be evidence of a paid claim or physician documented use with any ONE of the following: o One inhaled mast cell stabilizer o One oral albuterol product o One oral theophylline containing product by the patient within the previous 130 days. 3

4 There must be evidence of a BCBSMA paid claim or physician documented use of Symbicort (Budesonide/Formoterol) by the patient within the previous 130 days*, There must be evidence of a BCBSMA paid claim of Breo TM Ellipta TM or Anoro TM Ellipta TM by the patient within the previous 130 days **Requests based exclusively on the use of samples will not meet coverage criteria for exception. Additional clinical information demonstrating medical necessity of the desired medication must be submitted by the requesting prescriber for review. We do not cover the above listed medications for allergies, allergic reactions, or chronic urticaria unless the above step therapy criteria are met. Individual Consideration All our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual s unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to: Blue Cross Blue Shield of Massachusetts Clinical Pharmacy Department One Enterprise Drive Quincy, MA Tel: Fax: Managed Care Authorization Instructions Physicians may call BCBSMA Pharmacy Operations department to request a review for prior authorization for patients who do not meet the step-therapy criteria at the point of sale. Pharmacy Operations: (800) Physicians may also fax or mail the attached form to the address above. The Formulary Exception/Prior Authorization form is included as part of this document for physicians to submit for patients who do not meet the step therapy criteria at the point of sale. Physicians may also submit requests for retail pharmacy exceptions via the web using Express PAth which can be found on the BCBSMA provider portal or directly on the web at PPO and Indemnity Authorization Instructions Physicians may call BCBSMA Pharmacy Operations department to request a review for prior authorization for patients who do not meet the step-therapy criteria at the point of sale. Pharmacy Operations: (800) Physicians may also fax or mail the attached form to the address above. The Formulary Exception/Prior Authorization form is included as part of this document for physicians to submit for patients who do not meet the step therapy criteria at the point of sale. Physicians may also submit requests for retail pharmacy exceptions via the web using Express PAth which can be found on the BCBSMA provider portal or directly on the web at Policy History Date Action 10/2014 Added Anoro TM Ellipta TM to the policy. 4/2014 Updated by moving montelukast & zafirlukast to Step 1 and Advair to step 3. 3/2014 Added Breo TM Ellipta TM to the policy. 4

5 1/2014 Updated ExpressPAth language and remove Blue Value 8/2012 Updated to include coverage criteria for new generic montelukast 11/2011- Medical policy ICD 10 remediation: Formatting, editing and coding updates. 4/2012 1/1/2012 Updated to include coverage criteria for COPD diagnosis and to remove physician documented use criteria for requested medications. 5/2011 Reviewed - Medical Policy Group - Pediatrics and Endocrinology. 3/2011 Reviewed - Medical Policy Group - Allergy/Asthma/Immunology and ENT/Otolaryngology. 1/2011 Updated to include coverage criteria for new generic zafirlukast. 1/1/2011 Updated coverage criteria to require previous use of one inhaled corticosteroid, one inhaled beta 2 agonist, one inhaled mast cell stabilizer, one oral albuterol product or one oral theophylline containing product by the patient within the previous 130 days for a diagnosis of asthma. 11/2010 Updated to include coverage criteria of new FDA approved medication Dulera. 5/2010 Reviewed - Medical Policy Group - Pediatrics. 3/2010 Reviewed - Medical Policy Group - Pulmonology, Allergy and ENT/Otolaryngology. 1/2010 Updated to change coverage criteria for Advair Diskus and Advair HFA. 9/2009 Policy updated to change 180 day look back period to 130 days, remove Medicare Part D criteria from Medical Policy and update sample language. 5/2008 Reviewed - Medical Policy Group - Pediatrics. 3/2008 Reviewed - Medical Policy Group - Pulmonology, Allergy and ENT/Otolaryngology. 1/2008 Updated include prior authorization requirements for Advair Diskus,Advair HFA and Symbicort. 5/2007 Reviewed - Medical Policy Group - Pediatrics. 3/2007 Reviewed - Medical Policy Group - Pulmonology, Allergy and ENT/Otolaryngology. 2/2003 New policy, effective 2/2003, describing covered and non-covered indications. References 1. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165: Krawiec, ME., Jarjour,NJ, Leukotriene Receptor Antagonists 95(7): , Southern Medical Association. 3. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: Curr Opin Allergy Clin Immunol 2(5): , Lippincott Williams & Wilkins. 5. Semin Respir Crit Care Med 23(4): , Thieme Medical Publishers. 6. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma Located at: Accessed on: 11/3/ National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics Located at: Accessed on: 11/3/ Breo TM Ellipta TM [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May Anoro TM Ellipta TM [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May

6 Endnotes A.) Based upon the recommendation of the BCBSMA Pharmacy and Therapeutics Committee, 10/2002. B.) Based upon the recommendation of the BCBSMA Pharmacy and Therapeutics Committee, 9/2007. C.) Based upon the recommendation of the BCBSMA Pharmacy and Therapeutics Committee, 9/2009 6

7 Request for Outpatient Retail Pharmacy Prior Authorization Fax to: Clinical Pharmacy Program (800) Phone Authorization (800) or Web: To ensure that we can confirm your request (required by NCQA), please be sure to include your fax number. We cannot process requests unless they contain all of the information requested below: Patient Information (REQUIRED) Name BCBSMA ID number Is the patient a BCBSMA employee? If yes, please fax request to: (617) Yes No Date of Birth Patient s Diagnosis Physician Information (REQUIRED) Name Medical Specialty BCBSMA Provider number/npi# Telephone Number Fax Number Is this fax number secure for PHI receipt/transmission per HIPAA requirements? (circle one) Yes No Contact Name (if different from physician) Please select one of the three following sections to complete, depending on the nature of your request for the above-named patient. Formulary Exception Request Name of non-covered drug you want to prescribe Reason for Individual Consideration Request (please check one): Treatment failure with the following covered drugs in class Documented adverse reaction to the following covered drugs Other clinical reason (please specify) Quality Care Dosing Override Request Drug name, strength and quantity requested: Clinical reason for override (please specify) Outpatient Retail Pharmacy Prior Authorization Request Drug name: Start/End date (must be one year or less): Associated Co-morbid diagnosis: MD Signature: Date: 7

Pharmacy Medical Policy IgE Receptor Binding Inhibitors

Pharmacy Medical Policy IgE Receptor Binding Inhibitors Pharmacy Medical Policy IgE Receptor Binding Inhibitors Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References

More information

Pharmacy Medical Policy Angiotensin II Receptor Antagonists

Pharmacy Medical Policy Angiotensin II Receptor Antagonists Pharmacy Medical Policy Angiotensin II Receptor Antagonists Table of Contents Policy: Commercial Information Pertaining to All Policies Endnotes Policy: Medicare References Forms Policy History Policy

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Pharmacy Medical Policy Natalizumab (Tysabri )

Pharmacy Medical Policy Natalizumab (Tysabri ) Pharmacy Medical Policy Natalizumab (Tysabri ) Table of Contents Policy: Commercial Information Pertaining to All Policies Endnotes Coding Information References Forms Policy History Policy Number: 062

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan See Important Reminder

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective

More information

Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection

Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection Pharmacy Medical Policy Bisphosphonates and Monoclonal Antibodies, Infusion/Injection Table of Contents Policy: Commercial Policy History References Coding Information Information Pertaining to All Policies

More information

Key features and changes to these four components of asthma care include:

Key features and changes to these four components of asthma care include: Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

FASENRA (benralizumab)

FASENRA (benralizumab) FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

benralizumab (Fasenra )

benralizumab (Fasenra ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

2. Does the patient have chronic urticaria? Y N

2. Does the patient have chronic urticaria? Y N Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17 Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Pharmacy Medical Policy Alglucerase (Ceredase and Cerezyme ) for Gaucher Disease

Pharmacy Medical Policy Alglucerase (Ceredase and Cerezyme ) for Gaucher Disease Pharmacy Medical Policy Alglucerase (Ceredase and Cerezyme ) for Gaucher Disease Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE: LEVALBUTEROL HFA (levalbuterol tartrate) inhalation aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:

Clinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date: Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:

Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered: Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid

More information

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly

More information

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy

More information

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date: Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,

More information

A Partnership in Quality Reporting. Effectiveness of Care: Prevention and Screening

A Partnership in Quality Reporting. Effectiveness of Care: Prevention and Screening A Partnership in Quality Reporting Effectiveness of Care: Prevention and Screening Codes to Identify Well-Child Visits Completed during First 15 Months of Life ICD-9-CM Diagnosis Codes 99381, 99382, 99391,

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

Cinqair (reslizumab injection for intravenous use)

Cinqair (reslizumab injection for intravenous use) Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Strep Test 87070, 87071, 87081, Pharyngitis (CWP)

Strep Test 87070, 87071, 87081, Pharyngitis (CWP) Clinical Excellence Measures Use of these codes should be appropriate to the service(s) rendered and follow the billing guidelines. For HEDIS measures the codes are from the NCQA HEDIS specifications and

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PMN.69 Effective Date: 11/15 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Orally Inhaled Corticosteroids to 2022

Orally Inhaled Corticosteroids to 2022 Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table

More information

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:

More information

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date:

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Combination Beta2-Agonist/Corticosteroid Inhalers

Combination Beta2-Agonist/Corticosteroid Inhalers Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet

ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet pteronyssinus) allergen extract sublingual tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.

More information

Nucala (mepolizumab injection for subcutaneous use)

Nucala (mepolizumab injection for subcutaneous use) Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Inhaled Corticosteroid Dose Comparison in Asthma

Inhaled Corticosteroid Dose Comparison in Asthma This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

Asthma. Definition. Symptoms

Asthma. Definition. Symptoms Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

Clinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:

Clinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date: Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

The prevalence and severity of chronic asthma have

The prevalence and severity of chronic asthma have An Economic Analysis of Alternative Step-Up Therapies in Asthma Patients Receiving Inhaled Daniel A. Ollendorf, MPH, Alyssa S. Pozniak, BA, Brian W. Bowers, PharmD, Gerry Oster PhD ABSTRACT We analyzed

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: KARBINAL ER (carbinoxamine maleate) extended release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Drug Prior Authorization Guideline NUCALA (mepolizumab) Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and

More information

Medications Affecting The Respiratory System

Medications Affecting The Respiratory System Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The

More information

Diagnosis and Management of Asthma

Diagnosis and Management of Asthma Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:

More information

1.* Dosage. A. Adults

1.* Dosage. A. Adults Aerosolized Agents (Metered-Dose Inhalers) - Inhaled Anti-Inflammatory Drugs: Corticosteroids [Developed, January 1995; Revised, February, 1997; August 1997; March 1998; February 1999; January 2000; March

More information

LOKELMA (sodium zirconium cyclosilicate) oral suspension

LOKELMA (sodium zirconium cyclosilicate) oral suspension LOKELMA (sodium zirconium cyclosilicate) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are:

The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are: For 2016 the Clinical Integration Program is moving its clinical quality measures from the Verisk Healthcare Quality and Risk Measures to the National Committee for Quality Assurance HEDIS based measures.

More information

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Commissioner for the Department for Medicaid Services Selections for Preferred Products Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for

More information

Q: Should patients with mild asthma

Q: Should patients with mild asthma 1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions

More information

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR) Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Indacaterol/Glycopyrrolate (Utibron Neohaler) Reference Number: CP.PMN.147 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,

More information

Asthma By Mayo Clinic staff

Asthma By Mayo Clinic staff MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints

More information

ASTHMA IN THE PEDIATRIC POPULATION

ASTHMA IN THE PEDIATRIC POPULATION ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center

More information

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date: Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

End Stage COPD Guidance Document

End Stage COPD Guidance Document End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

기관지확장제와기관지천식 치료에쓰이는약물 이종호 한림의대약리학교실

기관지확장제와기관지천식 치료에쓰이는약물 이종호 한림의대약리학교실 기관지확장제와기관지천식 치료에쓰이는약물 이종호 한림의대약리학교실 천식치료제 기관지확장제 Beta2 adrenergic agonists; terbutaline, albuterol, metaproterenol, salmeterol Muscarinic antagonists; Ipratropium Methylxanthines; theophylline 예방및항염증약물

More information

Lungs SLO Practice (online) Page 1 of 5

Lungs SLO Practice (online) Page 1 of 5 Lungs SLO Practice (online) Page 1 of 5 1. A 15 year- old teen has asthma. A nebulizer treatment has been ordered. The type of medication most likely to be used in this treatment for asthma management

More information

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. RAGWITEK (Short Ragweed Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline

More information

Asthma and COPD Drug Discoveries:

Asthma and COPD Drug Discoveries: Asthma and COPD Drug Discoveries: What the future holds World Leaders in Health Industry Analysis Asthma and COPD Drug Discoveries: what the future holds ISBN: 1 85822 264 8 Copyright 2006 Espicom Business

More information

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association ABCBS PCMH 2016 Specifications An Independent Licensee of the Blue Cross and Blue Shield Association Table of Contents I. Terminology 3 II. Transformation Activities 2016 List of Activities 4 3 month 5-9

More information

Drug Use Criteria: Leukotriene Receptor Antagonists

Drug Use Criteria: Leukotriene Receptor Antagonists Texas Vendor Drug Program Drug Use Criteria: Leukotriene Receptor Antagonists Publication History Developed February 2007. Revised March 2016; June 2014; October 2012; November 2010; October 2010; September

More information

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior

More information

Formulary Medical Necessity Program

Formulary Medical Necessity Program BENEFIT APPLICATION Formulary Medical Necessity Program DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. Metformin tablet SR 24-hour modified release oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

XOLAIR (omalizumab) Prior Authorization

XOLAIR (omalizumab) Prior Authorization MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists

More information

STEP THERAPY IN MEDICARE PART D

STEP THERAPY IN MEDICARE PART D STEP THERAPY IN MEDICARE PART D Sarkis Kavarian, PharmD Candidate 15 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1 st, 2015 Objectives Why is this important? Medicare Part

More information

Copyright 2012 Oregon State University. All Rights Reserved

Copyright 2012 Oregon State University. All Rights Reserved Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Step 2: Identify patients who were dispensed at least two consecutive fills for any asthma medication (Table ACT-A: Asthma

Step 2: Identify patients who were dispensed at least two consecutive fills for any asthma medication (Table ACT-A: Asthma NATIONAL QUALITY FORUM Measure Submission and Evaluation Worksheet 5.0 This form contains the information submitted by measure developers/stewards, organized according to NQF s measure evaluation criteria

More information

LEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector

LEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information